Share This Page
Suppliers and packagers for CANGRELOR
✉ Email this page to a colleague
CANGRELOR
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Gland | CANGRELOR | cangrelor | POWDER;INTRAVENOUS | 213551 | ANDA | Gland Pharma Limited | 68083-412-10 | 10 VIAL, SINGLE-DOSE in 1 CARTON (68083-412-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE | 2025-08-11 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for CANGRELOR
Cangrelor suppliers: contract manufacturers, API sources, and downstream packaging options
Cangrelor (an investigational IV P2Y12 antagonist; commonly discussed under the trade name cangrelor) has no established, widely publicized global supply chain comparable to marketed brands. Public procurement, Orange Book-style exclusivity, and FDA commercial manufacturing references are not consistently available in the open literature for “cangrelor” as a standalone product. As a result, no complete, accurate supplier map can be produced without risking incorrect identification of API or finished-product manufacturers.
Which companies supply cangrelor API and drug substance?
No complete, reliable open-source listing of cangrelor API suppliers (drug substance) is available in the provided information.
How do API supplier identifications typically surface for investigational IV cardiology drugs?
For investigational small molecules, candidate suppliers are usually identifiable via one or more of the following public channels:
- patent assignees naming manufacturing examples
- clinical trial drug supply disclosures (protocol attachments, investigator brochures)
- corporate filings and CMC packages submitted to regulators (rarely public in full)
- import/manufacturing site disclosures in FDA inspection databases (requires exact product/label identifiers)
No such identifiers are present in the provided context.
Who manufactures finished cangrelor injection (drug product)?
No complete, reliable open-source listing of finished-dose cangrelor injection manufacturers is available in the provided information.
Are cangrelor manufacturing sites tied to specific dosage forms or strengths?
Open disclosures for cangrelor are typically limited to clinical development documentation, where:
- the same site may produce multiple strengths
- packaging format may vary by protocol or geography
- labeling may reference sponsor or clinical supply codes rather than the active supplier’s name
No exact dosage form, strength, NDC, or labeler/manufacturer is available here to anchor the supplier search.
What contract development and manufacturing organizations (CDMOs) handle cangrelor?
No CDMO-to-cangrelor attribution can be stated accurately from the provided information.
Which suppliers provide cangrelor clinical trial drug supply?
No complete, reliable list of clinical trial drug suppliers for cangrelor can be produced from the provided information.
How do cangrelor trial supplies usually get sourced?
For investigational IV agents in acute coronary syndromes, drug supply is typically structured through:
- sponsor-led procurement from one or two qualified manufacturers
- split allocation across geographies based on study sites
- batch-specific release tied to stability and sterile manufacturing records
No study identifiers or sponsor manufacturing disclosures are present in the provided context.
How does cangrelor compare with other P2Y12 IV antagonists in supply chain visibility?
A structured comparison cannot be made without naming specific comparator drugs and establishing their supplier rosters from the same evidence class. The provided information contains no such drug or supplier baseline.
What patent-anchored suppliers can be identified for cangrelor?
No patent-to-supplier mapping can be produced from the provided information.
How do patents usually reveal manufacturing sources for small-molecule drugs?
Patent documents may disclose:
- synthetic routes with named intermediates and example scale-ups
- formulation examples (where applicable)
- assignee identities, which sometimes correlate with development manufacturing partners
No patent numbers, assignees, or example manufacturing references are included in the provided context.
What regulatory filings identify cangrelor manufacturing sites?
No regulatory filing-based supplier list can be produced without an FDA application number, labeler identity, or an extractable public dossier.
Key Takeaways
- A complete, accurate supplier roster for cangrelor (API and finished drug product) cannot be provided from the supplied information.
- Supplier identification for investigational IV drugs typically requires sponsor protocol drug-supply disclosures, patent example manufacturing assignments, FDA/Cles labeling identifiers, or site inspection links. None are present in the provided context.
FAQs
- Which firms make cangrelor injection for clinical trials?
- Who are the cangrelor API manufacturers (drug substance suppliers)?
- What CDMOs supply cangrelor sterile IV manufacturing?
- Do cangrelor manufacturing sites show up in public FDA inspection records?
- How can patent assignees be used to infer cangrelor manufacturing partners?
References
No sources were cited because no cangrelor supplier-identifying evidence was provided in the prompt.
More… ↓
